What is HC Wainwright’s Estimate for UNCY Q2 Earnings?

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Equities researchers at HC Wainwright cut their Q2 2026 earnings estimates for shares of Unicycive Therapeutics in a research note issued to investors on Tuesday, June 30th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.32) for the quarter, down from their prior estimate of ($0.27). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.29) EPS, FY2026 earnings at ($1.45) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.16) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.06 EPS, FY2027 earnings at ($0.37) EPS, FY2028 earnings at $3.04 EPS, FY2029 earnings at $4.57 EPS and FY2030 earnings at $5.42 EPS.

A number of other brokerages also recently issued reports on UNCY. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, June 9th. Benchmark lowered their price objective on Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a research report on Wednesday. Noble Financial dropped their target price on Unicycive Therapeutics from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Wednesday. Guggenheim reaffirmed a “buy” rating and set a $37.00 target price (down from $40.00) on shares of Unicycive Therapeutics in a research report on Wednesday, May 13th. Finally, Wall Street Zen cut Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Unicycive Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $27.40.

Unicycive Therapeutics Stock Up 8.5%

Shares of UNCY opened at $5.73 on Friday. The company has a market cap of $156.94 million, a price-to-earnings ratio of -2.59 and a beta of 1.79. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $8.74. The company has a 50 day moving average of $7.43 and a two-hundred day moving average of $6.81.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

Hedge Funds Weigh In On Unicycive Therapeutics

Several hedge funds have recently made changes to their positions in UNCY. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics in the 2nd quarter worth $55,000. JPMorgan Chase & Co. lifted its position in Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock worth $104,000 after acquiring an additional 21,525 shares during the period. Renaissance Technologies LLC purchased a new stake in Unicycive Therapeutics during the 1st quarter valued at about $161,000. Citadel Advisors LLC acquired a new position in shares of Unicycive Therapeutics in the third quarter valued at about $182,000. Finally, Bank of America Corp DE increased its holdings in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares during the period. 40.42% of the stock is owned by institutional investors and hedge funds.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Negative Sentiment: Investors are reacting to reports that Unicycive received a second FDA Complete Response Letter, with articles saying the agency cited third-party manufacturing deficiencies. That keeps regulatory uncertainty high and appears to be the main pressure on the stock. Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
• Negative Sentiment: Multiple law firms, including Kirby McInerney, Bragar Eagel & Squire, and Block & Leviton, announced securities-fraud investigations tied to the FDA update, which can add overhang and worsen investor sentiment. UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT
• Negative Sentiment: HC Wainwright and Noble Financial sharply reduced near-term earnings estimates for 2026 and 2027, signaling more caution around the company’s path to profitability even though both firms kept bullish ratings. MarketBeat UNCY analyst updates
• Neutral Sentiment: Despite the estimate cuts, analysts such as HC Wainwright and Noble Financial still have Buy/Outperform ratings and price targets well above the current share price, which may help limit downside if investors focus on longer-term commercialization potential. MarketBeat UNCY analyst updates

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.